Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
GENETIC SIGNATURES LIMITED (GSS)ASX AI Signals has generated 3 signal for GSS during the last 90 days, indicating active trading activity and ongoing AI monitoring
Latest GSS Signals | |
| 29/06/2026 | SELL |
| 28/06/2026 | SELL |
| 27/06/2026 | SELL |
GSS Share Price | |
| Current Price | $0.068 |
| 52 Week High | $0.420 |
| 52 Week Low: | $0.058 |
| Trading at (% of 52 Week High) | 16.19% |
Genetic Signatures Limited (ASX: GSS) is an Australian company that develops and commercializes molecular diagnostic tests. The company specializes in rapid, accurate detection of infectious diseases using its proprietary PCR technology. Its products are used in healthcare and research settings worldwide.
The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.
The SELL recommendation for GENETIC SIGNATURES LIMITED (GSS) is supported by weak price momentum and potential liquidity concerns at the current low price level. However, some volatility and sector-specific developments could affect the stock, warranting a high but not very high confidence level.
The Australian market has been showing signs of potential growth, with materials leading the charge and most sectors in the green, hinting at a possible early Santa Rally. In such an environment, penny stocks—often smaller or newer companies—can offer intriguing opportunities for investors willing t It hasn't been the best quarter for Genetic Signatures Limited (ASX:GSS) shareholders, since the share price has fallen 22% in that time. But that doesn't change the fact that shareholders have received really good returns over the last five years. We think most investors would be happy with the 159 When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 14x, you may consider Genetic Signatures Limited (ASX:GSS) as a stock to avoid entirely with its 76.9x P/E ratio. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for Every investor in Genetic Signatures Limited (ASX:GSS) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. Companies that have been privatized tend to have low insider It is hard to get excited after looking at Genetic Signatures' (ASX:GSS) recent performance, when its stock has declined 6.5% over the past three months. However, the company's fundamentals look pretty decent, and long-term financials are usually aligned with future market price movements. ParticulaLatest GENETIC SIGNATURES LIMITED(GSS) News
ASX Penny Stocks With Market Caps Under A$3B
Genetic Signatures' (ASX:GSS) investors will be pleased with their splendid 159% return over the last five years
There's Reason For Concern Over Genetic Signatures Limited's (ASX:GSS) Price
Do Institutions Own Genetic Signatures Limited (ASX:GSS) Shares?
Should Weakness in Genetic Signatures Limited's (ASX:GSS) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial